CO6160324A2 - Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario - Google Patents
Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetarioInfo
- Publication number
- CO6160324A2 CO6160324A2 CO09029291A CO09029291A CO6160324A2 CO 6160324 A2 CO6160324 A2 CO 6160324A2 CO 09029291 A CO09029291 A CO 09029291A CO 09029291 A CO09029291 A CO 09029291A CO 6160324 A2 CO6160324 A2 CO 6160324A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- group
- aryl
- arylalkyl
- cyano
- Prior art date
Links
- 229910052757 nitrogen Inorganic materials 0.000 title abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- -1 -NR72 Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 150000003536 tetrazoles Chemical group 0.000 abstract 1
- 229930192474 thiophene Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
1.- Un compuesto que tienen la fórmula (I):caracterizado porqueY1 se selecciona a partir del grupo que consiste de N, NH, O, CR5 y CH2; Y2 se selecciona a partir del grupo que consiste de CO, CH2, CH y N, cada R1, R2 y R3 se selecciona independientemente a partir del grupo que consiste de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -NR72, alcoxi C1-6, halógeno, haloalquilo C1-6, hidroxialquilo C1-6, ciano, -C(O)R6, cicloalquilo C3-6, cicloalquilo C3-6-alquilo C1-6, arilo y arilalquilo C1-6, en donde cada una de dichas porciones alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y arilo, es opcionalmente sustituida con desde 1 hasta 3 sustituyentes, cada uno seleccionado independientemente a partir del grupo que consiste de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, amino, alcoxi C1-6, halógeno, hidroxilo, ciano, oxo, tio, cicloalquilo C3-6, arilo y heteroarilo. R4 es H o -(CH2)mCO2H; R5 se selecciona a partir de H, alquilo C1-6, ciano, halógeno, haloalquilo C1-6, arilo, arilalquilo C1-6 y -C(O)R6;R6 se selecciona a partir del grupo que consiste de H, hidroxi, alquiloC1-6, alcoxi C1-6, heterociclilalcoxi C1-6 y -NR72;cada R7 se selecciona independientemente a partir del grupo que consiste de H, alquilo C1-6 y arilalquilo C1-6 u opcionalmente, dos grupos R7 unidos al nitrógeno son combinados con el átomo de nitrógeno para formar un anillo azetidina, pirrolidina, piperidina o morfolina, en donde cada uno de dicho alquilo C1-6 y arilalquilo C1-C6 es opcionalmente sustituido con desde 1 hasta 3 sustituyentes, cada uno seleccionado independientemente a partir del grupo que consiste de halógeno, amino, hidroxilo, alcoxi C1-6, ciano, alquilo C1-6, cicloalquilo C3-6, arilo, y heteroarilo. cada Ar1 y Ar2 representa un anillo aromático seleccionado a partir del grupo que consiste de benceno, piridina, pirazina, pirimidina, tetrazol y tiofeno, cada uno de los cuales es opcionalmente sustituido con desde 1-2 sustituyentes R8, ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84632806P | 2006-09-20 | 2006-09-20 | |
| US11/856,616 US7834023B2 (en) | 2006-09-20 | 2007-09-17 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6160324A2 true CO6160324A2 (es) | 2010-05-20 |
Family
ID=39048759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09029291A CO6160324A2 (es) | 2006-09-20 | 2009-03-20 | Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7834023B2 (es) |
| EP (1) | EP2094272B1 (es) |
| JP (1) | JP5266232B2 (es) |
| KR (1) | KR20090057314A (es) |
| AU (1) | AU2007299723A1 (es) |
| BR (1) | BRPI0718444A2 (es) |
| CA (1) | CA2664411A1 (es) |
| CO (1) | CO6160324A2 (es) |
| HK (1) | HK1131058A1 (es) |
| IL (1) | IL197726A0 (es) |
| MA (1) | MA30775B1 (es) |
| MX (1) | MX2009003017A (es) |
| NO (1) | NO20091331L (es) |
| NZ (1) | NZ576162A (es) |
| RU (1) | RU2009114827A (es) |
| TN (1) | TN2009000091A1 (es) |
| WO (1) | WO2008036843A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100260825A1 (en) * | 2009-04-13 | 2010-10-14 | Nair Madhavan G | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches |
| WO2012177896A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| PE20140868A1 (es) | 2011-06-24 | 2014-07-18 | Amgen Inc | Antagonistas trpm8 y su uso en tratamientos |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| JP6745824B2 (ja) | 2015-06-26 | 2020-08-26 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3788054B1 (en) * | 2018-04-30 | 2022-07-20 | Unity Biotechnology, Inc. | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL135175B2 (en) * | 1983-12-22 | 1985-10-31 | Method of printing of articles made of polyamide fibres | |
| DE19650975A1 (de) * | 1996-12-09 | 1998-06-10 | Basf Ag | Neue heterocyclisch substituierte Benzamide und deren Anwendung |
| DK1163237T3 (da) | 1999-03-17 | 2004-08-02 | Astrazeneca Ab | Amidderivater |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| FR2837201A1 (fr) | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2005097276A (ja) * | 2003-08-22 | 2005-04-14 | Takeda Chem Ind Ltd | 縮合ピリミジン誘導体およびその用途 |
| KR20060113700A (ko) | 2003-10-03 | 2006-11-02 | 포톨라 파마슈티컬스, 인코포레이티드 | 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아 |
| MXPA06003625A (es) * | 2003-10-03 | 2006-08-11 | Portola Pharm Inc | Isoquinolinonas sustituidas. |
| CA2568756A1 (en) | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
| US20070010537A1 (en) * | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
| CA2581638A1 (en) | 2004-09-29 | 2006-04-13 | Portola Pharmaceuticals, Inc. | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| EP2035386A1 (en) | 2006-06-19 | 2009-03-18 | AstraZeneca AB | Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases |
-
2007
- 2007-09-17 US US11/856,616 patent/US7834023B2/en not_active Expired - Fee Related
- 2007-09-20 EP EP07842909.9A patent/EP2094272B1/en active Active
- 2007-09-20 NZ NZ576162A patent/NZ576162A/en not_active IP Right Cessation
- 2007-09-20 RU RU2009114827/15A patent/RU2009114827A/ru not_active Application Discontinuation
- 2007-09-20 CA CA002664411A patent/CA2664411A1/en not_active Abandoned
- 2007-09-20 JP JP2009529403A patent/JP5266232B2/ja not_active Expired - Fee Related
- 2007-09-20 WO PCT/US2007/079076 patent/WO2008036843A2/en active Application Filing
- 2007-09-20 MX MX2009003017A patent/MX2009003017A/es active IP Right Grant
- 2007-09-20 BR BRPI0718444-1A2A patent/BRPI0718444A2/pt not_active IP Right Cessation
- 2007-09-20 AU AU2007299723A patent/AU2007299723A1/en not_active Abandoned
- 2007-09-20 KR KR1020097007782A patent/KR20090057314A/ko not_active Application Discontinuation
-
2009
- 2009-03-19 TN TN2009000091A patent/TN2009000091A1/fr unknown
- 2009-03-19 IL IL197726A patent/IL197726A0/en unknown
- 2009-03-20 CO CO09029291A patent/CO6160324A2/es unknown
- 2009-03-31 NO NO20091331A patent/NO20091331L/no not_active Application Discontinuation
- 2009-04-02 MA MA31756A patent/MA30775B1/fr unknown
- 2009-11-17 HK HK09110735.0A patent/HK1131058A1/xx not_active IP Right Cessation
-
2010
- 2010-10-26 US US12/912,367 patent/US20110098247A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090057314A (ko) | 2009-06-04 |
| MX2009003017A (es) | 2009-06-08 |
| HK1131058A1 (en) | 2010-01-15 |
| NO20091331L (no) | 2009-05-20 |
| RU2009114827A (ru) | 2010-10-27 |
| NZ576162A (en) | 2012-03-30 |
| BRPI0718444A2 (pt) | 2013-11-19 |
| JP2010504357A (ja) | 2010-02-12 |
| AU2007299723A1 (en) | 2008-03-27 |
| US20110098247A1 (en) | 2011-04-28 |
| US7834023B2 (en) | 2010-11-16 |
| WO2008036843A3 (en) | 2008-05-15 |
| US20080132499A1 (en) | 2008-06-05 |
| MA30775B1 (fr) | 2009-10-01 |
| TN2009000091A1 (en) | 2010-08-19 |
| IL197726A0 (en) | 2009-12-24 |
| EP2094272B1 (en) | 2014-03-26 |
| WO2008036843A2 (en) | 2008-03-27 |
| CA2664411A1 (en) | 2008-03-27 |
| EP2094272A2 (en) | 2009-09-02 |
| JP5266232B2 (ja) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6160324A2 (es) | Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| CY1118879T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| CY1112914T1 (el) | Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης | |
| ECSP11010912A (es) | Compuestos de pirrol | |
| AR076067A1 (es) | Composiciones y metodos para modular la senda de senalizacion de wnt | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| ECSP088129A (es) | Derivado novedoso de heterocicliden acetamida | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| CO6361956A2 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmaceúticas que los contienen | |
| NI201000011A (es) | Derivados de pirimidina 934. |